Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 10th European Nephrology Conference Rome, Italy.

Day 1 :

Keynote Forum

John Mellas

St. Mary’s Health Center, USA

Keynote: The description of a method to accurately measure creatinine clearance in acute kidney injury

Time : 10:00-10:40

OMICS International Nephrology Conference 2016 International Conference Keynote Speaker John Mellas photo
Biography:

John Mellas, MD, has been practicing nephrology for thirty years in St. Louis, Missouri. He is the Senior Partner in the largest nephrology practice in St. Louis. He is also Chairman of the Nephrology Division at St. Mary’s Health Center where he is actively involved in teaching internal medicine trainees. He has developed a method to measure creatinine clearance in acute kidney injury and has been using it in his practice for the last several years. A detailed description of the method was published in Mathematical Biosciences in March 2016, titled, “The Description of a Method to Accurately Measure Creatinine Clearance in Acute Kidney Injury”. His talk will describe the logic behind the derivation of the method with patient examples provided to illustrate its use in the evaluation of the patient with acute kidney injury.

 

Abstract:

Background: Acute kidney injury (AKI) is a common and serious condition encountered in hospitalized patients. The severity of kidney injury is defined by the RIFLE, AKIN and KDIGO criteria which attempts to establish the degree of renal impairment. The KDIGO guidelines state that the creatinine clearance should be measured whenever possible in AKI and that the serum creatinine concentration and creatinine clearance remain the best clinical indicators of renal function. Neither the RIFLE, AKIN, nor KDIGO criteria estimate actual creatinine clearance. Furthermore, there are no accepted methods for accurately estimating creatinine clearance in AKI.

Study Design: The present study describes a unique method for estimating K in AKI using urine creatinine excretion over an established time interval (E), an estimate of creatinine production over the same time interval (P), and the estimated static glomerular filtration rate (sGFR), at time zero, utilizing the CKD-EPI formula. Using these variables estimated creatinine clearance (Ke)=E/P*sGFR.

Setting & Participants: The method was tested for validity using simulated patients where actual creatinine clearance (Ka) was compared to Ke in several patients, both male and female, and of various ages, body weights and degrees of renal impairment. These measurements were made at several serum creatinine concentrations in an attempt to determine the accuracy of this method in the non-steady state. In addition, E/P and Ke was calculated in hospitalized patients, with AKI, and seen in nephrology consultation by the author. In these patients the accuracy of the method was determined by looking at the following metrics; E/P>1, E/P<1, E=P in an attempt to predict progressive azotemia, recovering azotemia, or stabilization in the level of azotemia respectively. In addition, it was determined whether Ke<10 ml/min agreed with Ka and whether patients with AKI on renal replacement therapy could safely terminate dialysis if Ke was greater than 5 ml/min.

Outcomes & Results: In the simulated patients, there were 96 measurements in 6 different patients where Ka was compared to Ke. The estimated proportion of Ke within 30% of Ka was 0.907 with 95% exact binomial proportion confidence limits. The predictive accuracy of E/P in the study patients was also reported as a proportion and the associated 95% confidence limits: 0.848 (0.800, 0.896) for E/P<1; 0.939 (0.904, 0.974) for E/P>1 and 0.907 (0.841, 0.973) for 0.95 ml/min accurately predicted the ability to terminate renal replacement therapy in AKI.

Limitations: This includes the need to measure urine volume accurately. Furthermore, the precision of the method requires accurate estimates of sGFR, while a reasonable measure of P is crucial for estimating Ke.

Conclusions: the present study provides the practitioner with a new tool to estimate real time K in AKI with enough precision to predict the severity of the renal injury, including progression, stabilization, or improvement in azotemia. It is the author’s belief that this simple method improves on RIFLE, AKIN and KDIGO for estimating the degree of renal impairment in AKI and allows a more accurate estimate of K in AKI.

Keynote Forum

Roger E De Filippo

Children’s Hospital of Los Angeles, USA

Keynote: Injection of amniotic fluid stem cells delays progression of renal fibrosis

Time : 10:40-11:20

OMICS International Nephrology Conference 2016 International Conference Keynote Speaker Roger E De Filippo photo
Biography:

Roger E De Filippo completed his MD at the Keck School of Medicine, University of Southern California, in 1993. He completed a Pediatric Urology Fellowship in 2003 at Boston Children’s Hospital, Harvard Medical School and did two years of Tissue Engineering research during his fellowship training. He is Chief of Pediatric Urology at Children’s Hospital Los Angeles and Co-Director of the GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics. He has published close to 50 manuscripts in reputed journals and presently serves on the Editorial Board of the journal Stem Cells Translational Medicine

Abstract:

Introduction: Alport syndrome (AS) is a hereditary form of chronic kidney disease (CKD) and is also a valuable model for studying progressive renal fibrosis and end stage renal disease (ESRD). Herein, we investigate the therapeutic potential of amniotic fluid stem cells (AFSC), which are not only well established to possess pluripotential characteristics but also demonstrate anti-fibrotic properties that may potentially lead to better therapies for AS and/or other fibrotic diseases of the kidney.

Methods: In this study, we have administered AFSCs in a murine model of AS (Col4a5-/-) before the onset of proteinuria. Mice were sacrificed at 5 days, 1 and 2 month(s) post treatment and kidneys were harvested for molecular and histological analysis. Kidney function was assessed with serum creatinine, BUN as well as proteinuria measurements.

Results: Systemic infusion of AFSC resulted in delayed renal fibrosis and prolonged animal survival, slower progression of glomerulosclerosis and ameliorated kidney function. Treated mice presented lower myofibroblast transformation in the kidney interstitial space, accompanied with down-regulated expression of inflammatory and cytokines such as IL-1, TNFα and TGFβ. Furthermore, AFSC injected mice presented significantly less glomerulosclerosis as much as 2.5 months post stem cell treatment when compared to their untreated siblings. Injected animals exhibited decreased recruitment and activation of M1 type macrophages and an apparent preference towards M2 type macrophages; which are thought to favor tissue remodeling. AFSCs do not differentiate into podocyte-like cells and they do not stimulate the production of collagen IVa5, needed for correct glomerular basement membrane assembly and function. Our investigation supports a mechanism of renal protection through paracrine/endocrine modulation of expression of cytokines promoting fibrosis and macrophage recruitment to the interstitial space. Furthermore, injected mice manifested preservation of the number of podocytes and improved integrity of the glomerular basement membrane. These beneficial effects may be promoted by interference with the renin-angiotensin system by the AFSCs.

Conclusion: In this study, we have shown that AFSCs are capable of slowing down the progression of Alport disease by incurring structural and functional benefits to the kidney. Although injection of AFSC does not entirely reverse kidney disease, taken together, our findings suggest that a single AFSC treatment delays progression of CKD and significantly improves survival in treated AS mice. These cells may present an alternative approach to treat various medical conditions where currently therapeutic options are either limited or inadequate.

Break: Networking and Refreshment Break 11:20-11:40 @ Foyer